Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene

Biochemical Pharmacology

Volumn 78, Issue 5, 2009, Pages 523-530

  Nagasawa, Michiaki ^a   Hara, Tomoko ^a   Kashino, Ai ^a   Akasaka, Yunike ^a   Ide, Tomohiro ^a   Murakami, Koji ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Apolipoprotein; HepG2 cells; KRP 101; PPAR ; PPRE; RXR

Indexed keywords

APOLIPOPROTEIN A4; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; RETINOID X RECEPTOR ALPHA;

ARTICLE; BINDING SITE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FLANKING REGION; DNA PROTEIN COMPLEX; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE DELETION; GENE LOCATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION;

APOLIPOPROTEINS A; BASE SEQUENCE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MUTAGENESIS, SITE-DIRECTED; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROMOTER REGIONS, GENETIC;

EID: 67649482317     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.007     Document Type: Article

References (37)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
2. Keller H., and Wahli W. Peroxisome proliferator-activated receptors. Trends Endocrinol Metab 4 (1993) 291-296
3. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999;97:p. 161-3.
4. Beck F., Plummer S., Senior P.V., Byrne S., Green S., and Brammar W.J. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat. Proc R Soc Lond B: Biol Sci 247 (1992) 83-87
5. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137 (1996) 354-366
6. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46 (1997) 1319-1327
7. Schoonjans K., Staels B., and Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907-925
8. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771-774
9. Gearing K.L., Göttlicher M., Teboul M., Widmark E., and Gustafsson J.A. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 90 (1993) 1440-1444
10. Palmer C.N., Hsu M.H., Muerhoff A.S., Griffin K.J., and Johnson E.F. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. J Biol Chem 269 (1994) 18083-18089
11. Nagasawa M., Akasaka Y., Ide T., Hara T., Kobayashi N., Utsumi M., et al. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells. Biochem Pharmacol 74 (2007) 1738-1746
12. Utermann G., Beisiegel U., and Apolipoprotein. A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem 99 (1979) 333-343
13. Lefevre M., and Roheim P.S. Metabolism of apolipoprotein A-IV. J Lipid Res 25 (1984) 1603-1610
14. Elshourbagy N.A., Boguski M.S., Liao W.S., Jefferson L.S., Gordon J.I., and Taylor J.M. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci USA 82 (1985) 8242-8246
15. Ghiselli G., Krishnan S., Beigel Y., and Gotto Jr. A.M. Plasma metabolism of apolipoprotein A-IV in humans. J Lipid Res 27 (1986) 813-827
16. Cohen R.D., Castellani L.W., Qiao J.H., Van Lenten B.J., Lusis A.J., and Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 99 (1997) 1906-1916
17. Weinstock P.H., Bisgaier C.L., Hayek T., Aalto-Setala K., Sehayek E., Wu L., et al. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J Lipid Res 38 (1997) 1782-1794
18. Qi L., Liu S., Rifai N., Hunter D., and Hu F.B. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 192 (2007) 204-210
19. Goldberg I.J., Scheraldi C.A., Yacoub L.K., Saxena U., and Bisgaier C.L. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 265 (1990) 4266-4272
20. Fujimoto K., Cardelli J.A., and Tso P. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 262 (1992) G1002-G1006
21. Fujimoto K., Fukagawa K., Sakata T., and Tso P. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 91 (1993) 1830-1833
22. Ostos M.A., Conconi M., Vergnes L., Baroukh N., Ribalta J., Girona J., et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 1023-1028
23. Nagasawa M., Ide T., Suzuki M., Tsunoda M., Akasaka Y., Okazaki T., et al. Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor alpha (PPARalpha) agonist in dogs. Biochem Pharmacol 67 (2004) 2057-2069
24. Osumi T., Wen J.K., and Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 175 (1991) 866-871
25. Nakshatri H., and Bhat-Nakshatri P. Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. Nucleic Acids Res 26 (1998) 2491-2499
26. Juge-Aubry C., Pernin A., Favez T., Burger A.G., Wahli W., and Meier CA. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. J Biol Chem 272 (1997) 25252-25259
27. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11 (1992) 433-439
28. Vu-Dac N., Gervois P., Jakel H., Nowak M., Bauge E., Dehondt H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278 (2003) 17982-17985
29. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.C., et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273 (1998) 25713-25720
30. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96 (1995) 741-750
31. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312-4317
32. Tsunoda M., Kobayashi N., Ide T., Utsumi M., Nagasawa M., and Murakami K. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet. Am J Physiol Endocrinol Metab 294 (2008) E833-840
33. Staels B., van Tol A., Andreu T., and Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 12 (1992) 286-294
34. Anderson S.P., Dunn C., Laughter A., Yoon L., Swanson C., Stulnig T.M., et al. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor, and liver X receptor in mouse liver. Mol Pharmacol 66 (2004) 1440-1452
35. Ferretti G., Baccheti T., Bicchiega V., and Curatola G. Effect of human apo A-IV against lipid peroxidation of very low density lipoproteins. Chem Phys Lipids 114 (2002) 45-54
36. Recalde D., Ostos M.A., Badell E., Garcia-Otin A.-L., Pidoux J., Castro G., et al. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 24 (2004) 756-761
37. Vowinkel T., Mori M., Krieglstein C.F., Russell J., Saijo F., Bharwani S., et al. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 114 (2004) 260-269